NEW YORK, Nov. 23, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter conducted exclusive interviews with the CEO's of BioMS Medical Corp. (TSX:MS); RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN); and Canopus BioPharma (Pink Sheets:CBIA) at the 4th Annual Acumen BioFin Rodman & Renshaw Global Healthcare Conference in New York City. The video interviews can be viewed for free at www.WallStreetReporter.com.
Patrick Prendercast, CEO of Canopus BioPharma (Pink Sheets:CBIA), discusses the company's innovative business plan and diverse portfolio. He describes the company's main segments; Mucositis, HIV, and Hepatitis C, noting that Canopus doesn't "touch a market if it isn't $1 Billion."
Highlights Include:
* The company's "well of products," including over 60 patents. * Canopus's innovative business plan of reinventing drugs for new indications. * Mr. Prendercast's expectations for the company's share price to triple in the very near future.
Another promising biopharmaceuticals company featured is BioMS Medical Corp. (TSX:MS). President and CEO Kevin Giese tells us about BioMS's primary drug, called MBP8298, for the treatment of Multiple Sclerosis.
Highlights Include:
* The only Phase III study with a novel therapeutic for Secondary Progressive Multiple Sclerosis in the world. * The large patient population and lack of competition in the Secondary Progressive MS market. * Management's plans to find a marketing partner.
Also featured, J.J. Finkelstein, President and CEO of RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN), discusses the company's five clinical trials. "Clinical trials are really where the value is created," Mr. Finkelstein explains. "(We) have five shots at gold, or so to speak," he adds.
Highlights Include:
* RegeneRx's Thymosin Beta 4 (TB4) technology platform. * Peer-reviewed research demonstrating TB4's efficacy in treating cardiovascular, dermal, and ophthalmic wounds in animals. * The company's outsourcing business model, which minimizes infrastructure costs.
Wall Street Reporter (Est. 1843) is the premier source of investment information on global small-cap public companies in high-growth sectors. Through their magazines, special reports, conferences, and website, WSR presents unique opportunities for discovering stocks before they appear on Wall Street's radar and become widely known and recommended among the "who's who" of the investment community.
These and other exclusive video interviews can be viewed at www.wallstreetreporter.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.